- Research works
- 2 fractional, all time
- Citations
- 9 5.2 per fractional work
- Top-10% rate
- 9.0% record average 16.5%
- Open access
- 88% world 28%
Not ranked overall: Hansoh Bio (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does Hansoh Bio (United States) publish most on?
By volume in 2022–2025: Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Protein Degradation and Inhibitors and Myeloproliferative Neoplasms: Diagnosis and Treatment.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Chronic Myeloid Leukemia Treatments Hematology 0 works
- 2 Chronic Lymphocytic Leukemia Research Genetics 0 works
- 3 Protein Degradation and Inhibitors Molecular Biology 0 works
- 4 Myeloproliferative Neoplasms: Diagnosis and Treatment Genetics 0 works
- 5 Kruppel-like factors research Molecular Biology 0 works
- 6 Genetic Syndromes and Imprinting Genetics 0 works
- 7 Protein purification and stability Molecular Biology 0 works
- 8 Transgenic Plants and Applications Biotechnology 0 works
- 9 Cancer Mechanisms and Therapy Pathology and Forensic Medicine 0 works
- 10 Epigenetics and DNA Methylation Molecular Biology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Hansoh Bio (United States)'s research output changed?
Other research institutions in Rockville
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.